Natera is today's selection for IBD 50 Stocks To Watch as the DNA testing company has grown 85% year to date. Natera stock is rebounding from its 50-day moving average as it tries to get past a buy point of 117.23, according to IBD MarketSurge chart analysis tools.
Shares attempted a breakout from a consolidation after the company reported second-quarter results on Aug. 8. Sales for the period accelerated for the third continuous quarter. And while the company lost money over the last eight quarters, losses improved during the Q2 reporting period that ended June 30.
Sales rose 58% to $413.4 million while the company reported a loss of 30 cents per share. That marked an improvement from a loss of 97 cents a share during the year-earlier quarter.
Natera Stock: Funds Buying Shares
Natera uses software and artificial intelligence in testing DNA that can be found outside cells as they circulate in the blood. The company provides testing for prenatal screening, cancer care and monitoring, and for anticipating rejections after organ transplants.
A rising number of funds have been net buyers of Natera stock during the last three quarters. The stock also boasts an Accumulation/Distribution Rating of A-. The Columbia Small Cap Growth Fund holds shares of Natera.
Natera stock holds a Relative Strength Rating of 96 out of a best-possible 99. The Composite Rating is considered adequate at 85 though the EPS Rating of 55 lags.
Please follow VRamakrishnan on X/Twitter for more news on the stock market today.
